Drug Database
BE

beclometasone dipropionate (Qvar RediHaler / Qvar BAI)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule

What is beclometasone dipropionate?

beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesQvar RediHaler, Qvar BAI
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

beclometasone dipropionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

beclometasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedThe Journal of asthma : official journal of the Association for the Care of Asthma2026-09-16

Comparative Surface Microbial Contamination of a Cardboard Spacer MDI PLUS® and Conventional Plastic Inhalation Devices under Simulated Repeated Use.

Ismail Ahlam A, Sobh Ahmed H M AHM, Harb Hadeer S HS, Madney Yasmin M YM et al.

Pressurized metered-dose inhalers and spacer devices repeatedly come in contact with the mouth, raising concerns regarding microbiological contamination during routine use. Limited data compares microbial contamination across different spacer materials under simulated real-world handling and storage conditions. We quantified external and internal-surface bioburden (CFU/cm2) on the plastic AeroChamber Plus® valved holding chamber, plastic pMDI mouthpieces, and the cardboard MDI PLUS® spacer at baseline and after a standardized use protocol of 20 actuations (4 actuations/day for 5 days) followed by 7 days of ambient storage. Testing was performed with salbutamol (100 µg), beclometasone (250 µg), and a beclometasone/salbutamol combination (250/100 µg). Organisms were cultured on selective media and identified by standard biochemical assays and Analytical Profile Index (API). Across all formulations and time points, the cardboard MDI PLUS® spacer consistently showed lower recoverable surface microbial contamination compared with the plastic devices (AeroChamber Plus® and pMDI mouthpiece). Gram-negative organisms, including Pseudomonas spp., were detected on plastic spacers and pMDI mouthpieces but were not recovered from the cardboard spacer under any condition. Total microbial counts on plastic devices ranged from approximately 40 - 48 CFU/cm2, whereas counts on the cardboard spacer remained lower, ranging from approximately 22 - 26 CFU/cm2. Candida albicans was detected on plastic devices, but was not recovered from the cardboard spacer following repeated use and storage in some formulations. Under simulated repeated use, the cardboard-based spacer exhibited lower recoverable surface microbial contamination than the conventional plastic inhalation devices. These data highlight the potential influence of device material on microbial retention and may inform device selection and hygiene practices in routine respiratory care.

PMID 42747948
Read full article →
PubMedERJ open research2026-09-15

Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy.

Canonica Giorgio Walter GW, Singh Dave D, Papi Alberto A, Brusselle Guy G et al.

There is growing interest in evaluating the ability of treatments to deliver clinical remission in patients with asthma. We conducted post hoc analyses of TRIMARAN and TRIGGER, two clinical studies comparing the efficacy and safety of fixed-dose combination beclometasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) (TRIMARAN, 100/6/10 μg and TRIGGER 200/6/10 µg) with BDP/FF (100/6 µg and 200/6 µg, respectively). Clinical remission was defined as: no use of oral corticosteroids over 52 weeks, no occurrence of severe exacerbations over 52 weeks, Asthma Control Questionnaire-5 score <1.5 at weeks 26, 40 and 52, and pre-dose forced expiratory volume in 1 s at week 52 equal to, or higher than, the baseline value. Of 2291 patients included in these analyses, 598 (26.1%) met the clinical remission definition (i.e. met all criteria) at week 52: 315 (27.4%) in TRIMARAN and 283 (24.8%) in TRIGGER. The proportion of patients who achieved clinical remission was higher in the BDP/FF/G group than in the BDP/FF group in both studies (29.4% and 29.6% in TRIMARAN and TRIGGER, respectively, versus 25.4% and 20.0%), with the difference reaching statistical significance in TRIGGER (odds ratio 1.70, 95% confidence interval 1.29-2.23; p<0.001) and when data were pooled (29.5% versus 22.7%; 1.44, 1.19-1.73; p<0.001). Among patients with asthma that was uncontrolled by an inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination prior to study entry, a higher proportion achieved clinical remission by switching to inhaled triple therapy than by continuing ICS/LABA.

PMID 42741602
Read full article →
PubMedFrontiers in veterinary science2026-09-10

Synergistic in-vitro activity of Fosinopril alone and in combination with imidocarb dipropionate against Babesia bovis.

Bhowmick Biswajit B, Lacy Paul A PA, Suarez Carlos E CE, Chung Chungwon J CJ

Bovine babesiosis, caused by Babesia bovis is a major cattle disease worldwide, particularly in tropical and subtropical regions. A commonly used drug for the control and treatment of babesiosis is imidocarb dipropionate (ID), which has proved effective against B. bovis. Nevertheless, its toxicity to ruminants and other mammals, along with the persistence of drug residues in meat and milk for several months after treatment, has led to restriction on its use. Furthermore, several reports indicate that complete parasite elimination is not obtained in some cases. Interestingly, the angiotensin-converting enzyme (ACE) inhibitor Fosinopril has been recently found to exhibit potent antibabesial activity against Babesia duncani. In this study, we investigated the in-vitro activity of Fosinopril alone and in fixed-ratio combinations with ID against the B. bovis Texas T2Bo isolate. Quantitative dose-response analyses of the in-vitro activity showed that Fosinopril exhibited measurable activity against the Babesia bovis T2Bo isolate, with an IC50 value of 541.2 nM, whereas ID demonstrated greater potency, with an IC50 value of 124.3 nM. When fixed-ratio combination studies were conducted to evaluate interactions between two drugs, the low-dose regimen Comb-4 (108 nM Fosinopril + 25 nM ID) was the only tested combination that met the predefined ΣFIC criterion for synergy (ΣFIC = 0.40). MDBK cells viability testing showed that ID reduced cell viability at the parasite-relevant concentration tested, whereas Fosinopril and the low-dose combination treatments maintained high MDBK cell viability under the same in-vitro screening conditions. Overall, these proof-of-concept in-vitro findings suggest that Fosinopril has potential as a repurposed therapeutic agent for the treatment of B. bovis-infection in cattle. Low-dose Fosinopril-ID combinations may provide a dose-sparing direction for future pharmacological studies.

PMID 42718422
Read full article →
PubMedCureus2026-09-06

Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease.

Caussade-Silvestrini Gerardo S GS, Gerena-Maldonado Cristina P CP, Rodríguez-Rivera Rafael E RE, Alvarado-Ramos Natalia A NA et al.

Upadacitinib, a selective JAK1 inhibitor approved for hidradenitis suppurativa (HS) and Crohn's disease (CD), has been implicated in paradoxical inflammatory reactions; however, upadacitinib-induced psoriasiform dermatitis in patients treated for HS has not been previously described to the best of our knowledge. We report a 55-year-old woman with HS, CD, rheumatoid arthritis, and systemic lupus erythematosus, receiving upadacitinib 30 mg daily, who developed a pruritic erythematous scaly plaque on the lower back without personal or family history of psoriasis. Punch biopsy demonstrated psoriasiform dermatitis with acanthosis, focal hypogranulosis, uniform elongation of rete ridges, spongiosis, parakeratosis, and a superficial perivascular lymphocytic infiltrate. Given upadacitinib's established efficacy for both HS and CD, the drug was continued, and topical augmented betamethasone dipropionate was initiated, achieving adequate control at two-week follow-up. This case inverts the established paradigm in which JAK inhibitors serve as rescue agents for paradoxical reactions triggered by anti-TNF-α biologics. Comparable psoriasiform eruptions have been reported with baricitinib and tofacitinib, primarily in rheumatoid arthritis, a comorbidity present in our patient and an important interpretive caveat. We hypothesize that interferon-gamma (IFN-γ)-mediated STAT1 dysregulation intrinsic to HS pathogenesis may lower the threshold for JAK inhibitor-induced immune imbalance, although this mechanism remains speculative and warrants further investigation. Paradoxically, upadacitinib has also resolved psoriasiform eruptions in HS, underscoring the bidirectional and unpredictable nature of JAK1 inhibitor-mediated immune modulation. Psoriasiform dermatitis may represent a paradoxical cutaneous reaction to upadacitinib in patients with HS, warranting vigilant dermatologic monitoring and further investigation into individual susceptibility factors.

PMID 42699819
Read full article →
PubMedVestnik otorinolaringologii2026-09-04

[Topical Therapy of Otitis Externa: Potential Use of Combined Preparations].

Baranov K K KK, Kotova E N EN, Vyazmenov E O EO, Titova E V EV et al.

To assess the potential use of a combined topical preparation in the form of ear drops containing chloramphenicol, clotrimazole, beclomethasone dipropionate, and lidocaine in the treatment of patients with acute otitis externa, based on the clinical presentation and characteristics of the microbiological profile. A retrospective analysis of medical records of 168 patients with acute otitis externa over a 5-year period was performed. The study included children older than 6 years and adult patients. All patients underwent otorhinolaryngological examination, culture-based microbiological testing of discharge from the external auditory canal with species identification, CFU/mL counts and analysis of antimicrobial susceptibility data for clinically significant bacterial isolates according to laboratory reports, as well as local therapy with a combined topical preparation in the form of ear drops containing chloramphenicol, clotrimazole, beclomethasone dipropionate, and lidocaine. In cases where inflammation spread to the skin of the auricle, a combined ointment containing chloramphenicol and methyluracil was additionally used. Treatment efficacy was assessed based on the dynamics of subjective symptoms and objective signs of inflammation; tolerability was evaluated according to the presence of adverse events. Statistical analysis included calculation of mean values and proportions. Positive clinical dynamics were observed with the use of the combined topical ear drop preparation in patients with acute otitis externa: therapy resulted in regression of the main symptoms in 96.4% of patients, including reduction of otalgia, edema, hyperemia of the external auditory canal skin, and pathological discharge. Combined topical therapy with an ear drop preparation demonstrated high efficacy and a favorable safety profile in the treatment of acute otitis externa in children older than 6 years and adult patients, providing positive clinical dynamics in 96.4% of patients.

PMID 42693983
Read full article →
PubMedPathogens (Basel, Switzerland)2026-08-27

Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected with Babesia aktasi.

Ulucesme Mehmet Can MC, Ozubek Sezayi S, Aktas Munir M

Babesia aktasi is a recently discovered species that is highly prevalent in native goats in Türkiye's Mediterranean region. Although it does not induce clinical disease in local breeds, it causes severe illness in Saanen goats, manifesting with high fever, anemia, hemoglobinuria, and jaundice. Imidocarb dipropionate (IMDP) has been reported to be therapeutically effective against Babesia species. This study aimed to evaluate the therapeutic efficacy of IMDP and its ability to eliminate the parasite in experimentally infected Saanen goats. Twelve goats were assigned to treatment and control groups (n = 5 per group) and infected using fresh blood from two splenectomized donors. All goats developed clinical babesiosis, with parasitemia ranging from 3.8% to 22. Semi-nested PCR specific to B. aktasi was performed for 30 days post-treatment. Following treatment with IMDP (1.2 mg/kg), clinical signs resolved by the third and fourth days, and parasitemia became microscopically undetectable. However, one goat in the treatment group and four goats in the control group died shortly after infection. Hematological parameters (HCT, RBC, HB) decreased during infection but normalized in surviving animals. Notably, B. aktasi DNA remained detectable by PCR up to 30 days after treatment. These findings indicated that IMDP resolved clinical signs and eliminated microscopically detectable parasitemia; however, it may not completely eliminate the parasite at the molecular level in B. aktasi infections. The results of this study provide valuable information for optimizing therapeutic approaches and improving our understanding of treatment responses in new species B. aktasi.

PMID 42654770
Read full article →

+3756 more articles available with a free account

Sign up free to view all articles →

Ask about beclometasone dipropionate